Telehealth Dermatology Services

Telehealth dermatology — also called teledermatology — applies remote communication technologies to the clinical assessment, diagnosis, and management of skin, hair, and nail conditions without requiring an in-person encounter. This page covers the definition and regulatory scope of teledermatology, the two primary delivery mechanisms, the condition categories most commonly addressed remotely, and the clinical boundaries that determine when in-person care is required instead. Understanding these boundaries matters because dermatology has one of the longest specialist wait times in US medicine, and remote delivery models have reshaped how patients access care for both acute and chronic skin conditions.

Definition and scope

Teledermatology is a subspecialty application of telemedicine in which licensed dermatologists or supervised mid-level practitioners evaluate patients using digital imagery, video, or both. The American Academy of Dermatology (AAD) formally defines teledermatology as the use of telecommunications technology to provide dermatologic care at a distance, encompassing diagnosis, management consultation, and follow-up (AAD Position Statement on Teledermatology).

From a regulatory standpoint, teledermatology encounters are governed by the same federal and state frameworks that apply to telehealth broadly. The Centers for Medicare & Medicaid Services (CMS) recognizes teledermatology services under covered telehealth benefit categories, with reimbursement tied to Current Procedural Terminology (CPT) codes such as 99202–99215 for evaluation and management, and 96020 series codes for store-and-forward transmission. Parity obligations and coverage rules vary by payer and by state; the telehealth regulatory framework for the United States provides a broader orientation to those layered requirements.

The scope of teledermatology spans three functional categories:

1. Diagnostic consultation — a dermatologist reviews submitted images or conducts a live video encounter to provide a diagnosis or differential diagnosis.
2. Management and follow-up — ongoing monitoring of chronic conditions (psoriasis, atopic dermatitis, acne) through periodic remote visits.
3. Triage and referral support — a primary care provider submits images to a dermatologist for guidance on urgency and next steps, without a direct patient–specialist interaction.

How it works

Teledermatology operates through two distinct technical modalities, each with different workflow implications, reimbursement treatment, and clinical suitability.

Store-and-forward (asynchronous) is the dominant modality in dermatology. The patient or a referring clinician captures high-resolution photographs of the skin finding and submits them — along with relevant history — through a secure platform. A dermatologist reviews the case at a later time and issues a report or recommendation. This model does not require simultaneous availability of patient and provider. For a detailed framework comparison, see synchronous vs. asynchronous telehealth and store-and-forward telehealth.

Synchronous (live video) encounters occur in real time via videoconference. The dermatologist can ask follow-up questions, observe dynamic features such as dermographism or texture under directed lighting, and engage the patient directly. Live video is required when clinical decision-making depends on interaction or when the store-and-forward image quality is insufficient.

A typical store-and-forward workflow includes these discrete steps:

1. Patient or referring provider photographs the lesion using standardized image capture protocols (focus, lighting, scale reference).
2. Images and a structured intake form are uploaded through a HIPAA-compliant platform (telehealth HIPAA compliance requirements outlines the applicable security standards).
3. A board-certified dermatologist reviews the submission, typically within 24–72 hours depending on platform and urgency tier.
4. A written report is transmitted back to the referring provider or directly to the patient, depending on the care model.
5. The dermatologist recommends in-person follow-up, issues an ePrescription, or closes the case with documented findings.

Image quality is the principal technical constraint in both modalities. The AAD recommends minimum resolution standards for clinical photography, and inadequate images are the leading cause of inconclusive teledermatology consultations.

Common scenarios

Teledermatology is well-suited to conditions where visual assessment is the primary diagnostic tool and where the risk of missing a systemic finding through remote evaluation is low. Published utilization data from the Veterans Health Administration (VHA) — one of the largest teledermatology programs in the US — documents high concordance rates between teledermatology and in-person diagnoses for inflammatory and infectious skin conditions.

Condition categories frequently addressed through teledermatology include:

• Acne vulgaris — medication titration and follow-up are well-supported remotely.
• Atopic dermatitis and eczema — flare management, topical regimen adjustment.
• Psoriasis — disease severity scoring (PASI) adapted for remote use; biologic therapy monitoring in stable patients.
• Tinea infections — clinical presentation often sufficient for diagnosis from images.
• Contact dermatitis — pattern recognition and allergen history review.
• Benign pigmented lesions — mole mapping and surveillance photography for low-risk patients.
• Rosacea — subtype classification and trigger counseling.
• Seborrheic keratoses — reassurance and monitoring without biopsy.

Teledermatology also functions as a population-level access tool in rural and underserved settings. The Health Resources and Services Administration (HRSA) has funded teledermatology expansion specifically in Health Professional Shortage Areas (HPSAs), where in-person dermatology access may require travel exceeding 100 miles in frontier counties (HRSA Telehealth Programs).

Decision boundaries

Not all dermatologic concerns are appropriate for remote management. The AAD and the American Telemedicine Association (ATA) both identify clinical scenarios where in-person evaluation is required or strongly indicated.

In-person evaluation is indicated when:

1. A lesion requires dermoscopy with a calibrated handheld device — remote dermoscopy exists but depends on specialized attachment hardware not universally available to patients.
2. Biopsy is needed for definitive diagnosis — no remote model replaces tissue sampling.
3. The clinical presentation suggests melanoma or other skin malignancy with ambiguous features — high-risk lesion triage may begin remotely, but tissue diagnosis requires an in-person procedure.
4. Systemic involvement is suspected (e.g., lupus erythematosus, drug hypersensitivity reactions, Stevens-Johnson syndrome) — these require physical examination, labs, and potentially hospital-level care.
5. The patient is unable to provide adequate images due to lesion location, mobility limitations, or technology access barriers.
6. A previous teledermatology consultation was inconclusive.

Prescribing through teledermatology encounters is governed by state-specific prescribing laws and, where controlled substances are involved, by DEA regulations. The telehealth prescribing laws and limits reference covers the statutory framework. For conditions where isotretinoin (a Schedule X teratogen under the FDA iPLEDGE REMS program) is indicated, in-person pregnancy testing and labs are required regardless of the consultation modality (FDA iPLEDGE REMS).

Licensure is a hard boundary: the dermatologist must hold an active license in the state where the patient is located at the time of the encounter, absent an applicable interstate compact exception. The Interstate Medical Licensure Compact provides one pathway for multi-state practice, though compact participation varies by state and specialty board.

References

• American Academy of Dermatology — Teledermatology Position Statement
• Centers for Medicare & Medicaid Services — Telehealth Services
• Health Resources and Services Administration — Telehealth Programs
• American Telemedicine Association — Teledermatology Practice Guidelines
• FDA iPLEDGE REMS Program
• Veterans Health Administration — Teledermatology Program
• Office for Civil Rights — HIPAA and Telehealth